LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Arbutus Biopharma Corp

Aperta

4.02 -1.95

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.02

Massimo

4.17

Metriche Chiave

By Trading Economics

Entrata

27M

2.5M

Vendite

9M

11M

Margine di Profitto

23.494

Dipendenti

44

EBITDA

27M

2.6M

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

72M

711M

Apertura precedente

5.97

Chiusura precedente

4.02

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Arbutus Biopharma Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 set 2025, 23:59 UTC

Acquisizioni, Fusioni, Takeovers

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 set 2025, 22:02 UTC

I principali Market Mover

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 set 2025, 17:01 UTC

I principali Market Mover

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 set 2025, 17:01 UTC

I principali Market Mover

Tron Shares Rise After New Investment From Bravemorning

8 set 2025, 16:14 UTC

I principali Market Mover

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 set 2025, 16:13 UTC

I principali Market Mover

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 set 2025, 23:12 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 set 2025, 23:12 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 set 2025, 23:12 UTC

Discorsi di Mercato

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 set 2025, 22:56 UTC

Discorsi di Mercato

Worst May Be Over for New Zealand Retailers -- Market Talk

8 set 2025, 22:23 UTC

Discorsi di Mercato

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 set 2025, 21:51 UTC

Discorsi di Mercato

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 set 2025, 21:47 UTC

I principali Market Mover

Microsoft Signs $17.4B AI Deal With Nebius

8 set 2025, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 set 2025, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 set 2025, 21:19 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 set 2025, 21:18 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 set 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

8 set 2025, 19:33 UTC

Discorsi di Mercato

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 set 2025, 19:22 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 set 2025, 19:02 UTC

Discorsi di Mercato

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 set 2025, 18:24 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 set 2025, 18:24 UTC

Discorsi di Mercato

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 set 2025, 17:29 UTC

Discorsi di Mercato

Mexican Inflation Seen Little Changed in August -- Market Talk

8 set 2025, 16:59 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 set 2025, 16:36 UTC

Discorsi di Mercato

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 set 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

8 set 2025, 16:16 UTC

Utili

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 set 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 set 2025, 16:04 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Arbutus Biopharma Corp Previsione

Consenso sulla valutazione

By TipRanks

0 ratings

0

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

3.255 / 3.365Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Weak Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
help-icon Live chat